Indication

Prevention of kidney transplant rejection

Prevention of kidney transplant rejection refers to the therapeutic suppression of the recipient's immune response to avoid immune-mediated injury and subsequent failure of a donor renal allograft. Read more about Prevention of kidney transplant rejection

192 drugs 95 manufacturers

Advertisement

Drugs that treat it

Common Prevention of kidney transplant rejection therapies.

Showing 118–126 of 192 drugs

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
BPI LABS, LLC

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
A-S MEDICATION

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
GSMS, INC.

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+1
APOTEX CORP

MYCOPHENOLATE MOFETIL

IMMUNOSUPPRESSIVE INOSINE MONOPHOSPHATE DEHYDROGENASE INHIB.·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+2
PROFICIENT RX L

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
PROFICIENT RX L

TACROLIMUS

IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
BRYANT RANCH PR
Filter & compare in the drug finder →Opens the drug finder with Prevention of kidney transplant rejection preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Prevention of kidney transplant rejection.

Prevention of kidney transplant rejection refers to the therapeutic suppression of the recipient's immune response to avoid immune-mediated injury and subsequent failure of a donor renal allograft.

This clinical state occurs in kidney transplant recipients where foreign human leukocyte antigens on the donor organ provoke host cell-mediated and humoral immune reactions, predominantly driven by T-lymphocyte activation and donor-specific antibody production.

Left unmitigated, this alloimmune attack manifests pathologically as tubulitis, interstitial inflammation, vasculitis, or microvascular endothelial damage, clinically resulting in acute kidney injury, proteinuria, progressive allograft dysfunction, and graft loss.

Prophylaxis maintains target graft function and long-term organ survival by continuously inhibiting pathways of alloreactive immune recognition and effector cytotoxicity.

Personalize your experience

Follow Prevention of kidney transplant rejection and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it